Latest Blogs

Feb 21, 2019
I try to be clear when my approach is a recommendation based on the best data we have, and when it’s a suggestion in situations where reasonable clinicians may come to a different conclusion.
Feb 14, 2019
It's hard enough to try dating again after a cancer diagnosis and treatment, but some of my patients also face strong opposition from their adult children.
Feb 14, 2019
Dr. Suneel D. Kamath was surprised to learn how important laughter and levity can be in the physician-patient relationship.
Feb 11, 2019
When a patient asks, "Why me?", Dr. Stephanie Graff considers that they may not be asking for a list of their cancer risk factors.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a Professor Emeritus at the University of Colorado Cancer Center. He previously served as Chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Aug 31, 2018
Some reflections on John McCain, mortality, Hamilton, and the story you leave behind. 
Dec 21, 2016
I cannot count the number of times I have thought to myself, “If it were not for the PSA, you would no doubt be out there playing golf, skiing, biking, taking a grandchild to the park, or just enjoying life.” Living from one PSA to the next is a bad way to mark the passing of time.
Aug 08, 2016
For prostate cancer, there are both challenges and some early positive results from immunotherapy trials that remain intriguing. One of the key challenges is identifying those patients who will benefit from the treatment.
Jun 05, 2016
Much of the news this week in prostate cancer will be generated by the ASCO Annual Meeting in Chicago. There are likely to be considerable news releases regarding precision medicine, and especially AR-V7, so I thought I would explain this a bit.
Feb 16, 2016
In what is the first (and hopefully one of many) example of using modern genomic methods to match treatments to the molecular defects in prostate cancer, the U.S. FDA has just granted “breakthrough designation” to olaparib.
Jan 06, 2016
One of the most frequent questions I hear in my clinic is, “Are we making any progress?” or, “Is there anything new out there?” The answer is always yes, or more properly, YES!

Pages